IQ

IQVIA Holdings Inc.

IQVHealthcareNASDAQ

Diagnostics & Research · Last scanned Sep 8, 2026

PriceMA150MA200
Loading chart…
End-of-day data · ScananceOpen live chart on TradingView ↗
Indicator snapshot · Today
Premium
Today's indicator reading is locked

Free plan shows historical signals only. Upgrade to see this ticker's current MA150, MA200, RSI, and MACD readings.

Upgrade to see today →
Financials · Annual
Revenue
$16.31B
+5.9% YoY
Net Income
$1.36B
-0.9% YoY
EBITDA
$3.46B
+0.3% YoY
Free Cash Flow
$2.15B

Scan Results

Daily timeframe
8 recent days hidden. Fresh signals are a Premium featureUpgrade →
DateIndicatorDetails
Sep 3CONFIRMED MACD Negative CrossoverHistogram -0.4237, negative momentum
RSI OverboughtRSI 75.3, above 70, stock may be overbought
Sep 2CONFIRMED MACD Negative CrossoverHistogram -0.3859, negative momentum
RSI OverboughtRSI 71.4, above 70, stock may be overbought
About IQVIA Holdings Inc.

IQVIA Holdings Inc. provides clinical research services, commercial insights, and healthcare intelligence to the life sciences and healthcare industries in the Americas, Europe, Africa, and the Asia-Pacific. The $44.07B market capitalization puts IQV squarely in large-cap range for its industry. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.

Where IQV stands vs its 150-day and 200-day moving averages

As of the September 3, 2026 close, IQV finished 37.42% above its 150-day moving average ($191.99) and 31.02% above its 200-day moving average ($201.37). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.

Is IQV overbought or oversold?

At the September 3, 2026 close, IQV's RSI(14) was 75.3, in overbought territory (above 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.

Key stats
Market Cap$44.07B
P/E (TTM)33.35
Fwd P/E18.52
EPS$8.03
Beta1.19
52W Change+41.2%
ROE22.8%
Analysis

The company holds $2.08B in cash, though total debt stands at $16.25B. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. Annual free cash flow of $2.15B supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. Return on equity stands at 22.8%, which is strong for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. An ROA of 5.1% suggests reasonable efficiency in deploying the company's asset base. Revenue has been uneven over recent years, ranging from $14.41B to $16.31B.

IQVIA Holdings Inc. carries a heavier debt load relative to its cash position, which introduces financial risk that investors should weigh. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for IQVIA Holdings Inc. and its sector.

Links
More Healthcare stocks
Browse all stocks →
Not financial advice. Scanance shows end-of-day technical indicators (not real-time prices) for information only. Results can be wrong; past performance does not guarantee future results.PrivacyTerms